Research overview: anemia of feline CKD and erythropoiesis-stimulating agents

As feline CKD advances, reduced renal production of erythropoietin, along with iron dysregulation, inflammation, and shortened red cell survival, causes nonregenerative anemia that worsens weakness and quality of life. Erythropoiesis-stimulating agents, including recombinant human erythropoietin and later darbepoetin, can raise red cell counts, with darbepoetin generally favored for a lower risk of provoking antibodies that cause refractory anemia. This overview synthesizes the treatment literature rather than one citation, describing the multifactorial causes of renal anemia, why ESAs combined with iron support can improve clinical signs, and the importance of monitoring for complications such as hypertension and antibody formation. It matters because correcting anemia addresses a major contributor to the decline cats experience in advanced kidney disease.